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ABSTRACT Multidrug-resistant (MDR) Gram-negative organisms are a burden on
the global health care system. The Tigecycline Evaluation and Surveillance Trial
(TEST) is an ongoing global study designed to monitor the in vitro activities of tige-
cycline and a panel of marketed antimicrobials against a range of clinically signiﬁ-
cant pathogens. In this study, in vitro data are presented for MDR Acinetobacter bau-
mannii, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Klebsiella
oxytoca, Enterobacter aerogenes, and Enterobacter cloacae isolates collected from
2004 to 2014. In total, 13% (21,967/170,759) of isolates displayed multidrug resis-
tance globally, with the highest rates recorded among A. baumannii (overall rate,
44% [8,294/18,741], increasing from 23% [309/1,323] in 2004 to 63% [447/712] in
2014). Other multidrug resistance rates ranged from 2.5% for K. oxytoca (203/8,000)
to 12% for P. aeruginosa and K. pneumoniae (3,951/32,786 and 3,895/32,888, respec-
tively), and rates among these pathogens remained stable during the study period.
Against MDR E. coli, Klebsiella spp., and E. aerogenes, the lowest rates of resistance
were to tigecycline (0.2%, 6%, and 12%, respectively), and the lowest MIC90 value
against A. baumannii was observed for tigecycline (2 mg/liter; MIC range, 0.008 to
32 mg/liter). The only signiﬁcant change in resistance to tigecycline during the
study period was for MDR E. coli (P  0.01), among which eight resistant isolates
were identiﬁed globally from 2009 to 2013. In summary, these results show that
tigecycline retained in vitro activity against the majority of MDR Gram-negative or-
ganisms presented here, but the rising rates of MDR A. baumannii highlight the
need for the continued monitoring of global multidrug resistance.
IMPORTANCE Multidrug resistance among bacterial pathogens is an ongoing global
problem and renders antimicrobial agents ineffective at treating bacterial infections.
In the health care setting, infections caused by multidrug-resistant (MDR) Gram-
negative bacteria can cause increased mortality, longer hospital stays, and higher
treatments costs. The aim of the Tigecycline Evaluation and Surveillance Trial (TEST)
is to assess the in vitro antimicrobial activities of tigecycline and other contemporary
agents against clinically relevant pathogens. This paper presents antimicrobial activ-
ity data from the TEST study between 2004 and 2014 and examines global rates of
MDR Gram-negative isolates, including Acinetobacter baumannii, Pseudomonas
aeruginosa, and members of the Enterobacteriaceae, during this time. Our results
show that tigecycline retained in vitro activity against many MDR Gram-negative
pathogens over the study period, while rates of MDR A. baumannii increased glob-
ally. Using these ﬁndings, we hope to highlight the current status of multidrug resis-
tance in medical facilities worldwide.
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Multidrug resistance among Gram-negative organisms is a global problem, withrates of infections caused by multidrug-resistant (MDR) Gram-negative bacteria
increasing worldwide (1–3). MDR Gram-negative pathogens, such as Acinetobacter bau-
mannii, Pseudomonas aeruginosa, and the Enterobacteriaceae, are associated with in-
creased lengths of hospitalization, higher health care costs, and greater rates of
mortality (2, 4–6). These organisms have been highlighted as clinically important
bacteria, and some are included among the ESKAPE pathogens (an acronym for
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, A. baumanii, Pseu-
domonas aeruginosa, and Enterobacter spp.) (7).
Tigecycline is a broad-spectrum glycylcycline antimicrobial agent with in vitro
activity against both Gram-positive and Gram-negative organisms. Tigecycline has been
approved in the United States and Europe for the treatment of complicated skin and
intra-abdominal infections and also in the United States for community-acquired
bacterial pneumonia (8, 9). The in vitro activity of tigecycline is monitored globally,
alongside comparator agents, against clinical Gram-positive and Gram-negative isolates
as part of the Tigecycline Evaluation and Surveillance Trial (TEST). This study describes
the activity of tigecycline against MDR Gram-negative isolates collected globally be-
tween 2004 and 2014. Isolates collected during the earlier years of the study period
have been included in previous TEST publications, including reports focused on MDR
A. baumannii (10) and MDR Enterobacteriaceae (11) isolates that were collected in the
United States between 2004 and 2006 and on MDR Gram-negative isolates collected
globally between 2004 and 2013 (12).
RESULTS
Between 2004 and 2014, the majority of TEST centers were located in North America
and Europe (37% and 36%, respectively). Over the study period, 13% (21,967/170,759)
of Gram-negative isolates collected globally were MDR.
Acinetobacter baumannii. In total, 18,741 isolates of A. baumannii were collected
globally, of which 44% were reported to be MDR (Table 1). Global rates of MDR
A. baumannii isolates increased during the study period, from 23% in 2004 to 63% in
2014 (Fig. 1). By region, overall multidrug resistance among A. baumannii was lowest
in North America (31%) (Table 1). More than 50% of A. baumannii isolates collected in
Africa, the Middle East, and Latin America were MDR.
Overall, 95% of MDR A. baumannii isolates were resistant to ceftriaxone, and
approximately 90% of isolates were resistant to ceftazidime, levoﬂoxacin, meropenem,
and piperacillin-tazobactam (Table 2). Global resistance to levoﬂoxacin increased sig-
niﬁcantly from 92% (283/309) in 2004 to 96% (430/447) in 2014, and resistance to
piperacillin-tazobactam increased signiﬁcantly from 82% (252/309) in 2004 to 94%
(422/447) in 2014 (P  0.0001) (Table 3). The lowest levels of global resistance were
reported for minocycline (13%). The lowest MIC90 value was observed for tigecycline
(2 mg/liter), for which no breakpoints are available against A. baumannii.
Pseudomonas aeruginosa. MDR isolates accounted for 12% of the 32,786 P. aerugi-
nosa total isolates submitted (Table 1). Global rates of MDR P. aeruginosa increased
from 9% in the 2004-2005 period to 17% in the 2008-2010 period, and then the rate
decreased to 8% in 2014 (Fig. 1). Regionally, overall rates of multidrug resistance among
P. aeruginosa were lowest in North America (7%) and highest in Latin America (27%)
(Table 1). Among MDR P. aeruginosa isolates, the highest levels of global resistance
were reported to meropenem and levoﬂoxacin (92% to 96%) (Table 2). All agents had
limited activity against isolates of MDR P. aeruginosa (MIC90, 16 mg/liter).
Escherichia coli. Participating centers submitted a total of 42,261 E. coli isolates, of
which 8% were MDR (Table 1). Globally, rates of MDR E. coli increased from 5% in 2004
to 12% in the 2008-2009 period, and then decreased to 4% in the 2013-2014 period
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TABLE 1 Regional and global rates of MDR Gram-negative isolates collected between
2004 and 2014
Organism and
region
No. of
centersa
No. of MDR
isolates
Total no. of
isolates % MDR
Acinetobacter baumannii
Africa 17 249 407 61.2
Asia-Paciﬁc Rim 43 596 1,229 48.5
Europe 190 3,617 8,409 43.0
Latin America 58 1,560 2,213 70.5
Middle East 20 499 718 69.5
North America 169 1,773 5,765 30.8
Global 497 8,294 18,741 44.3
Pseudomonas aeruginosa
Africa 16 73 558 13.1
Asia-Paciﬁc Rim 46 327 1,772 18.5
Europe 192 1,777 14,951 11.9
Latin America 66 913 3,340 27.3
Middle East 21 129 989 13.0
North America 180 732 11,176 6.5
Global 521 3,951 32,786 12.1
Escherichia coli
Africa 13 58 731 7.9
Asia-Paciﬁc Rim 41 299 2,178 13.7
Europe 190 1,323 19,242 6.9
Latin America 65 795 4,492 17.7
Middle East 23 190 1,301 14.6
North America 157 557 14,317 3.9
Global 489 3,222 42,261 7.6
Klebsiella pneumoniae
Africa 16 111 668 16.6
Asia-Paciﬁc Rim 43 299 1,940 15.4
Europe 175 1,778 13,936 12.8
Latin America 62 709 3,704 19.1
Middle East 21 231 1,142 20.2
North America 145 767 11,498 6.7
Global 462 3,895 32,888 11.8
Klebsiella oxytoca
Africa 2 2 85 2.4
Asia-Paciﬁc Rim 8 14 245 5.7
Europe 62 113 4,639 2.4
Latin America 20 29 395 7.3
Middle East 8 14 106 13.2
North America 22 31 2,530 1.2
Global 122 203 8,000 2.5
Enterobacter aerogenes
Africa 3 5 94 5.3
Asia-Paciﬁc Rim 17 25 490 5.1
Europe 72 193 3,733 5.2
Latin America 25 72 583 12.3
Middle East 8 13 256 5.1
North America 48 73 3,297 2.2
Global 173 381 8,453 4.5
Enterobacter cloacae
Africa 11 37 494 7.5
Asia-Paciﬁc Rim 36 122 1,437 8.5
Europe 168 978 13,205 7.4
Latin America 55 387 2,771 14.0
Middle East 15 49 815 6.0
North America 143 448 8,908 5.0
Global 428 2,021 27,630 7.3
aThe number of TEST centers submitting MDR isolates. Not all centers submitted isolates during all study
years. The Asia-Paciﬁc Rim centers did not participate in TEST after 2010.
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(Fig. 1). Regional percentages of MDR E. coli ranged from 4% in North America to 18%
in Latin America (Table 1). Globally, nearly all MDR E. coli isolates tested were resistant
to levoﬂoxacin and ampicillin (98%), and 93% of isolates were resistant to minocy-
cline (Table 2). Global resistance to cefepime increased signiﬁcantly from 15% (18/117)
in 2004 to 46% (46/99) in 2014 (P  0.0001) (Table 3). The lowest level of resistance
globally was to tigecycline (0.2%). No tigecycline-resistant isolates were identiﬁed
between 2004 and 2008; however, eight resistant isolates were identiﬁed across regions
between 2009 and 2013 (Africa in 2012 [n  1], Europe in 2010 [n  1], Latin America
in 2009 [n  1], the Middle East in 2011 [n  1], and North America in 2011 [n  1],
2012 [n  1], and 2013 [n  2]). This change was statistically signiﬁcant (P  0.01)
(Table 3).
Klebsiella pneumoniae. Multidrug resistance was reported in 12% of 32,888 of
K. pneumoniae isolates submitted globally (Table 1). During the study period, global
rates of MDR K. pneumoniae increased from 4% in 2004 to 18% in 2010, and then
the rate decreased to 8% in 2014 (Fig. 1). By region, the lowest rates of MDR
K. pneumoniae were found in North America (7%), with the highest rates in Latin
America and the Middle East (19% and 20%, respectively) (Table 1). High levels of
global resistance were reported to ceftriaxone and levoﬂoxacin (89% and 94%,
respectively) (Table 2). Global resistance to amoxicillin-clavulanic acid, cefepime,
levoﬂoxacin, and piperacillin-tazobactam increased signiﬁcantly during the study
period: amoxicillin-clavulanic acid, 55% (46/83) in 2004 to 77% (113/147) in 2014;
cefepime, 61% (51/83) in 2004 to 88% (130/147) in 2014; levoﬂoxacin, 86% (71/83)
in 2004 to 97% (142/147) in 2014; piperacillin-tazobactam, 51% (42/83) in 2004 to
75% (110/147) in 2014 (P  0.0001) (Table 3). The lowest rate of resistance among
MDR K. pneumoniae was to tigecycline (6%).
Klebsiella oxytoca. Over the study period, 8,000 isolates of K. oxytoca were sub-
mitted globally, of which 2.5% were MDR (Table 1). The global rates of MDR K. oxytoca
increased from 0.4% in 2004 to 5% in the 2008-2009 period and then decreased to 0.6%
in 2014 (Fig. 1). The highest percentages of MDR K. oxytoca isolates were reported in the
Middle East (13%), while rates in all other regions were 7% (Table 1). More than 80%
of MDR K. oxytoca isolates collected globally were resistant to minocycline, ceftriaxone,
and levoﬂoxacin (86% to 91%) (Table 2). The lowest rate of resistance was to tigecycline
(6%).
Enterobacter aerogenes. Overall, 4.5% of 8,453 E. aerogenes isolates collected from
all regions were MDR (Table 1). Globally, the rates of MDR E. aerogenes increased from
3% in 2004 to 9% in 2008 but then decreased to 1% in 2014 (Fig. 1). There was a rate
FIG 1 Changes in global rates of MDR Gram-negative isolates collected between 2004 and 2014.
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TABLE 2 Global antimicrobial activity against MDR Gram-negative isolates collected
between 2004 and 2014
Organism (no. of isolates) and
antimicrobial agent
MIC (mg/liter) data Susceptibilitya
MIC90 Range % S % I % R
Acinetobacter baumannii (8,294)
Amikacin 128 0.5 to 128 20.1 7.7 72.2
Amoxicillin-clavulanic acid 64 1 to 64 —b — —
Ampicillin 64 0.5 to 64 — — —
Cefepime 64 0.5 to 64 5.3 13.6 81.2
Ceftazidime 64 1 to 64 4.1 5.3 90.7
Ceftriaxone 128 0.06 to 128 0.7 4.8 94.6
Levoﬂoxacin 16 0.03 to 16 2.3 7.9 89.8
Meropenem (7,338)c 32 0.06 to 32 6.9 3.0 90.1
Minocycline 16 0.5 to 32 68.6 18.9 12.6
Piperacillin-tazobactam 256 0.06 to 256 2.7 6.4 90.9
Tigecycline 2 0.008 to 32 — — —
Pseudomonas aeruginosa (3,951)
Amikacin 128 0.5 to 128 46.1 10.2 43.7
Amoxicillin-clavulanic acid 64 1 to 64 — — —
Ampicillin 64 0.5 to 64 — — —
Cefepime 64 0.5 to 64 7.7 22.5 69.8
Ceftazidime 64 1 to 64 11.5 11.0 77.5
Ceftriaxone 128 0.06 to 128 — — —
Levoﬂoxacin 16 0.03 to 16 2.1 1.5 96.4
Meropenem (3,392)c 32 0.06 to 32 4.5 2.9 92.6
Minocycline 32 0.5 to 32 — — —
Piperacillin-tazobactam 256 0.25 to 256 10.8 22.3 66.9
Tigecycline 32 0.008 to 32 — — —
Escherichia coli (3,222)
Amikacin 32 0.5 to 128 88.3 2.7 9.0
Amoxicillin-clavulanic acid 64 1 to 64 22.7 36.8 40.4
Ampicillin 64 0.5 to 64 0.6 0.1 99.3
Cefepime 64 0.5 to 64 49.6 12.6 37.8
Ceftriaxone 128 0.06 to 128 41.5 1.6 57.0
Levoﬂoxacin 16 0.008 to 16 1.4 0.2 98.4
Meropenem (2,814)c 0.25 0.06 to 32 92.9 1.1 6.0
Minocycline 32 0.5 to 32 5.2 2.0 92.8
Piperacillin-tazobactam 256 0.25 to 256 68.2 14.1 17.7
Tigecycline 1 0.008 to 32 99.5 0.2 0.2
Klebsiella pneumoniae (3,895)
Amikacin 128 0.5 to 128 68.5 11.8 19.7
Amoxicillin-clavulanic acid 64 0.5 to 64 10.7 19.5 69.8
Ampicillin 64 2 to 64 0.0 0.1 99.9
Cefepime 64 0.5 to 64 15.0 10.2 74.8
Ceftriaxone 128 0.06 to 128 10.1 0.9 89.0
Levoﬂoxacin 16 0.03 to 16 4.4 1.3 94.3
Meropenem (3,578)c 32 0.06 to 32 57.0 3.5 39.5
Minocycline 32 0.5 to 32 25.5 9.8 64.7
Piperacillin-tazobactam 256 0.12 to 256 21.5 13.7 64.8
Tigecycline 4 0.008 to 32 83.0 11.3 5.7
Klebsiella oxytoca (203)
Amikacin 128 0.5 to 128 76.8 5.4 17.7
Amoxicillin-clavulanic acid 64 0.25 to 64 12.8 21.7 65.5
Ampicillin 64 32 to 64 0.0 0.0 100
Cefepime 64 0.5 to 64 25.6 28.1 46.3
Ceftriaxone 128 0.06 to 128 13.3 0.0 86.7
Levoﬂoxacin 16 0.06 to 16 5.4 3.4 91.1
Meropenem (180)c 8 0.06 to 32 80.0 2.2 17.8
Minocycline 32 0.5 to 32 7.4 6.9 85.7
Piperacillin-tazobactam 256 0.06 to 256 34.5 12.8 52.7
Tigecycline 4 0.12 to 8 81.3 12.8 5.9
(Continued on following page)
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of 12% MDR E. aerogenes in Latin America and a rate of 5% in all other regions
(Table 1). More than 80% of isolates were resistant to levoﬂoxacin and ceftriaxone (83%
and 87%, respectively) (Table 2). The lowest levels of resistance were reported to
tigecycline (12%), followed by amikacin (21%).
Enterobacter cloacae. Among the 27,630 isolates of E. cloacae submitted globally,
a total of 7% were MDR (Table 1). Global rates of MDR E. cloacae increased from 4.5%
in 2004 to 10% in the 2008-2009 period, and then decreased to 4% in 2014 (Fig. 1). In
Latin America, 14% of E. cloacae isolates were MDR, compared with 9% of isolates in
all other regions (Table 1). The majority of MDR E. cloacae isolates collected globally
were resistant to levoﬂoxacin (85%), minocycline (89%), and ceftriaxone (90%) (Table 2).
Global resistance to cefepime increased signiﬁcantly, from 36% (28/78) in 2004 to 63%
(36/57) in 2014 (P  0.01) (Table 3). Resistance to tigecycline was the lowest reported
rate (15%).
DISCUSSION
This study describes the global rates of multidrug resistance among a selection of
clinically important Gram-negative organisms collected between 2004 and 2014, and it
shows the in vitro antimicrobial activity of tigecycline and a panel of other contempo-
rary antimicrobial agents against these resistant isolates.
Tigecycline retained in vitro activity against the majority of MDR organisms collected
between 2004 and 2014, with the exception of P. aeruginosa (MIC90, 32 mg/liter),
against which tigecycline is known to have limited activity (13). Furthermore, none of
the antimicrobial agents tested in the present study demonstrated potent in vitro
activity against MDR P. aeruginosa, which was highlighted among the ESKAPE organ-
isms as a cause for global concern (7). Against MDR A. baumannii, another of the
ESKAPE pathogens, tigecycline had the lowest MIC90 (2 mg/liter) of the agents on the
TEST panel. This MIC90 was comparable with that reported from a global study of
A. baumannii isolates collected between 2005 and 2009, which showed that tigecycline
inhibited 95% of MDR Acinetobacter spp. isolates at 2 mg/liter (14). Also, a study by
TABLE 2 (Continued)
Organism (no. of isolates) and
antimicrobial agent
MIC (mg/liter) data Susceptibilitya
MIC90 Range % S % I % R
Enterobacter aerogenes (381)
Amikacin 128 0.5 to 128 74.0 5.0 21.0
Amoxicillin-clavulanic acid 64 2 to 64 2.1 4.5 93.4
Ampicillin 64 16 to 64 0.0 0.5 99.5
Cefepime 64 0.5 to 64 38.3 21.3 40.4
Ceftriaxone 128 0.06 to 128 12.3 0.8 86.9
Levoﬂoxacin 16 0.06 to 16 13.9 2.9 83.2
Meropenem (321)c 16 0.06 to 32 67.9 3.1 29.0
Minocycline 32 0.5 to 32 15.0 8.1 76.9
Piperacillin-tazobactam 256 1 to 256 28.6 30.2 41.2
Tigecycline 8 0.015 to 16 66.9 20.7 12.3
Enterobacter cloacae (2,021)
Amikacin 128 0.5 to 128 75.4 4.4 20.2
Amoxicillin-clavulanic acid 64 0.25 to 64 0.5 1.9 97.6
Ampicillin 64 0.5 to 64 0.4 0.5 99.0
Cefepime 64 0.5 to 64 23.5 30.8 45.7
Ceftriaxone 128 0.06 to 128 7.7 1.9 90.5
Levoﬂoxacin 16 0.008 to 16 11.2 3.4 85.4
Meropenem (1,717)c 8 0.06 to 32 79.1 3.8 17.1
Minocycline 32 0.5 to 32 5.3 6.0 88.6
Piperacillin-tazobactam 256 0.06 to 256 26.0 20.8 53.2
Tigecycline 8 0.015 to 32 64.4 20.3 15.3
aS, susceptible; I, intermediate susceptibility; R, resistant.
b—, no breakpoints available.
cSusceptibility data for imipenem were collected from 2004 to 2006, after which time imipenem was
replaced with meropenem.
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Mammina et al. (15) of MDR A. baumannii from Palermo, Italy, reported tigecycline MICs
between 0.5 mg/liter and 4 mg/liter.
Among the MDR Enterobacteriaceae collected in this study, rates of resistance were
lowest to tigecycline. The overall global rates of tigecycline resistance among MDR
Enterobacteriaceae were 15% (357/2,402) for Enterobacter spp., 6% (235/4,098) for
Klebsiella spp., and 0.2% (8/3,222) for E. coli. Although the highest rates of tigecycline
resistance among MDR Enterobacteriaceae were recorded for Enterobacter spp., the
yearly rates of resistance among E. aerogenes and E. cloacae isolates ﬂuctuated between
1% and 42% during the study period, and this could be explained by the low numbers
of isolates submitted in some years. By year, the number of MDR E. aerogenes isolates
collected ranged from 6 in 2014 to 83 in 2008. Yearly totals of MDR E. cloacae isolates
were higher than those for MDR E. aerogenes isolates, but these totals only exceeded
200 isolates in four out of seven study years (2007 to 2010).
The overall global rate of tigecycline resistance among isolates of MDR Klebsiella
spp. in the current study was 6% (K. oxytoca, 12/203; K. pneumoniae, 223/3,895). For
MDR K. oxytoca isolates, the overall rate of tigecycline resistance may be difﬁcult to
interpret due to low isolate numbers (50 isolates collected per study year). Further-
more, tigecycline-resistant isolates were only identiﬁed in 2006 (19% [3/16]), 2008 (10%
[4/39]), 2009 (4% [2/50]), and 2011 (23% [3/13]). Two of the three tigecycline-resistant
K. oxytoca isolates collected in North America and Europe in 2006 and 2008, respec-
tively, were submitted by the same center from each region. This suggests a localized
incidence of tigecycline resistance during these two study years.
Higher numbers of MDR K. pneumoniae isolates were collected than numbers of
MDR K. oxytoca isolates, and global rates of tigecycline-resistant MDR K. pneumoniae
isolates ranged from 3% (4/147) to 11% (9/83). Despite this, the rates of tigecycline-
resistant MDR K. pneumoniae isolates decreased from 9% (27/307) in 2012 to 3% (4/147)
in 2014, which may signify the start of a decline in global resistance. Further surveil-
lance will be needed to follow this trend. In their study of blaKPC-carrying K. pneumoniae
in Palermo, Italy, Bonura et al. (16) reported a shift toward a polyclonal epidemic, which
highlights that the evolution of resistance is complex and that the importance of
changing patterns of resistance should not be underestimated.
In this study, the identiﬁcation of tigecycline-resistant MDR E. coli from 2009
onwards indicates that these organisms have recently acquired mechanisms of resis-
tance to the glycylcyclines. In the literature, occurrences of emerging tigecycline
resistance among patients with E. coli infections have been reported in the United
Kingdom (17) and in Italy (18). In both cases, E. coli isolates that were initially suscep-
tible to tigecycline in vivo became tigecycline resistant after prolonged antimicrobial
administration and, furthermore, in vitro the resistant isolates were found to produce
carbapenemases: New Delhi metallo--lactamase 1 (NDM-1) (17) and K. pneumoniae
carbapenemase 3 (KPC-3) (18). These carbapenemases are active against third-
generation cephalosporins and carbapenems; therefore, the acquisition of tigecycline
resistance likely confers an MDR phenotype. Stone et al. (17) reported the development
of resistance in vivo after 53 days of tigecycline treatment, and Spanu et al. (18)
reported resistance after 21 days of treatment. Despite these reports of development of
tigecycline resistance among E. coli isolates, the current TEST study shows that tigecy-
cline remains active against the majority of MDR E. coli isolates, and the TEST publica-
tion by Hoban et al. (12) reported that tigecycline was active against carbapenem-
resistant E. coli isolates collected between 2004 and 2013.
By organism, the highest overall rates of multidrug resistance reported in the present
study were among A. baumannii isolates, for which 44% of isolates collected globally
were MDR. By year, the results presented in Fig. 1 show an increase in the rates of MDR
A. baumannii during the study period, from 23% (309/1,323) in 2004 to 63% (447/712)
in 2014. The previous TEST publication by Garrison et al. (19) reported increasing global
rates of MDR A. baumannii isolates between 2004 and 2007, and Mendes et al. (14)
described a global increase in the rates of MDR Acinetobacter spp. between 2005 and
2009. Our report shows that multidrug resistance among A. baumannii isolates contin-
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ues to increase; given the limited treatment options for infections caused by such
organisms, this is a cause for concern.
The majority of MDR isolates collected globally were resistant to levoﬂoxacin, with rates
of resistance ranging from 83% of E. aerogenes isolates to 98% of E. coli. The World Health
Organization (WHO) recently published a report on global antimicrobial resistance that
included national data on rates of resistance from Africa, the Americas, Eastern Mediterra-
nean, Europe, Southeast Asia, and the Western Paciﬁc (20). In their report, resistance rates
among E. coli isolates of greater than 50% were reported to ﬂuoroquinolones in all regions
except Europe. They also showed that infections caused by ﬂuoroquinolone-resistant
E. coli isolates were associated with increased mortality. Fluoroquinolone resistance has
been linked with extended-spectrum -lactamase production among the Enterobacte-
riaceae (4, 6); therefore, extended-spectrum -lactamase production may be an indi-
cator of multidrug resistance.
Although global surveillance studies, such as TEST, have reported important infor-
mation on changes in antimicrobial activity and resistance, there are certain limitations
to the data presented. One such limitation is the yearly variation in the numbers of
participating centers. For example, the Asia-Paciﬁc region stopped submitting isolates
between 2010 and 2014. In this region, the rates of MDR A. baumannii isolates increased
from 29% (14/49) in 2005 to 60% (97/161) during the ﬁnal year of participation. The lack
of isolates from this region after 2010 will have impacted the global results. Further-
more, the majority of centers participating in TEST were located in Europe and North
America; therefore, changes in these regions could have had a greater impact on the
global data.
Despite these limitations, the data presented in this study show that tigecycline has
remained active against this global collection of Gram-negative pathogens. The collec-
tion of small numbers of tigecycline-resistant MDR E. coli isolates is of concern,
however, and highlights the importance for the continued surveillance of tigecycline
activity globally. The increasing rates of MDR A. baumannii isolates must also be
monitored, and this information should be used to aid health care facilities in reducing
MDR infections worldwide. Overall, more global studies of MDR pathogens are needed
if the ongoing problem of antimicrobial resistance is to be addressed.
MATERIALS AND METHODS
A total of 611 TEST centers submitted MDR Gram-negative isolates between 2004 and 2014. The
numbers of centers located in each study region were as follows: Africa, 20; Asia-Paciﬁc Rim, 52; Europe,
219; Latin America, 69; the Middle East, 23; North America, 228. Not all study centers submitted isolates
during all study years. Centers from the Asia-Paciﬁc Rim did not participate in the study after 2010.
Isolates were collected from all body sites from patients with known hospital- or community-acquired
infections.
MICs were determined in local laboratories using Clinical and Laboratory Standards Institute (CLSI)
guidelines for the broth microdilution methodology (21). Antimicrobial susceptibility was assessed using
breakpoints approved by the CLSI (22), except for tigecycline, for which the U.S. Food and Drug
Administration (FDA) breakpoints were used (8). Breakpoints were not available for tigecycline against
A. baumannii or P. aeruginosa isolates. Full methodology details for the TEST study have been published
previously (23).
In the current study, multidrug resistance was deﬁned as resistance to three or more classes of
antimicrobial agents. The classes used to deﬁne MDR isolates among the Enterobacteriaceae were
aminoglycosides (amikacin), -lactams (ampicillin, amoxicillin-clavulanic acid, cefepime, ceftriaxone,
or piperacillin-tazobactam), carbapenems (imipenem/meropenem), ﬂuoroquinolones (levoﬂoxacin), gly-
cylcyclines (tigecycline), and tetracyclines (minocycline); the classes used to deﬁne MDR A. baumannii
isolates were aminoglycosides (amikacin), -lactams (cefepime, ceftazidime, ceftriaxone, or piperacillin-
tazobactam), carbapenems (imipenem/meropenem), ﬂuoroquinolones (levoﬂoxacin), and tetracyclines
(minocycline); the classes used to deﬁne MDR P. aeruginosa isolates were aminoglycosides (amikacin),
-lactams (cefepime, ceftazidime, or piperacillin-tazobactam), carbapenems (imipenem/meropenem),
and ﬂuoroquinolones (levoﬂoxacin).
The Cochran-Armitage trend test was used to identify statistically signiﬁcant changes in susceptibility
between 2004 and 2014, with a cutoff value of P 0.01 to indicate signiﬁcance, due to the large number
of trend tests performed.
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